Speedel retains rights to anticlotting therapy SPP200

By Elaine Rigoli

Tampa, Fla., Aug. 16 - Speedel said Wednesday that it has retained all development, commercialization and marketing rights to SPP200 after completing a successful phase 2 trial in patients undergoing chronic hemodialysis.

For strategic portfolio considerations, Abbott Laboratories has now decided not to exercise its license-back option for SPP200. Abbott acquired the product through the acquisition of Knoll AG in 2002 before out-licensing it to Speedel in 2003.

Based on the promising results from the phase 2 trial, Speedel said it is evaluating all options and will be consulting with the Food and Drug Administration in the fourth quarter to seek its input.

"SPP200 gives Speedel the opportunity to retain an asset and add further value to our mature and diverse pipeline. We will be considering all options, from both clinical and economical perspectives, before deciding the most appropriate next steps," chief executive officer Alice Huxley said in a news release.

SPP200 is designed to prevent clot formation and is not removed from the patient's body during dialysis, unlike unfractionated heparin, which in the United States is the gold standard anticoagulant in hemodialysis, the release said.

Speedel said SPP200 has the potential to protect these patients from clotting events both during and between dialysis sessions.

Speedel is a public biopharmaceutical company located in Basel, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.